Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials

Publisher： John Wiley & Sons Inc

E-ISSN： 2047-9980|5|2|JAHA.116.003258-JAHA.116.003258

ISSN： 2047-9980

Source： JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol.5, Iss.2, 2016-02, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Sample Size Justification in Phase III/IV Clinical Trials

By  

Neuroepidemiology, Vol. 17, Iss. 2, 1998-04 ,pp. : 63-66

Karger

Access to resources Recommend Favorite

The clinical impact of bleeding during oral anticoagulant therapy: Assessment of morbidity, mortality and post-bleed anticoagulant management

By Guerrouij Minna  

Journal of Thrombosis and Thrombolysis, Vol. 31, Iss. 4, 2011-05 ,pp. : 419-423

Springer Publishing Company

Access to resources Recommend Favorite

Ethical Issues in Microbicide Clinical Trials for HIV Prevention

By  

Current HIV Research, Vol. 10, Iss. 1, 2012-01 ,pp. : 105-112

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study

By Hiwatashi Nobuo   Suzuki Yasuo   Mitsuyama Keiichi   Munakata Akihiro   Hibi Toshifumi  

Journal of Gastroenterology, Vol. 46, Iss. 1, 2011-01 ,pp. : 46-56

Springer Publishing Company

Access to resources Recommend Favorite

Ticagrelor: from discovery to Phase III clinical trial

By Siller-Matula Jolanta M   Jilma Bernd  

Future Cardiology, Vol. 6, Iss. 6, 2010-11 ,pp. : 753-764

Future Medicine

Access to resources Recommend Favorite